WWW - Posts tagged Epilepsy at BloggingStocks

epilepsy posts

GlaxoSmithKline Gets Good News from FDA Regarding Epilepsy Drug

Posted Aug 12th 2010 1:40PM by Brent Archer (RSS feed)
Filed under: Good news, Options, Technical Analysis

GlaxoSmithKline (GSK - option chain) shares are rising today after the company said an FDA advisory panel unanimously backed its epilepsy drug, ezogabine. GSK codeveloped the drug with Valeant Pharmaceuticals (VRX). If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on AMGN.

GSK opened this morning at $37.17. So far today the stock has hit a low of $37.00 and a high of $37.39. As of 12:15, GSK is trading at $37.22 up 0.76 (2.1%). The chart for GSK looks neutral and S&P gives GSK a neutral 3 STARS (out of 5) hold ranking.

Continue reading GlaxoSmithKline Gets Good News from FDA Regarding Epilepsy Drug

Pfizer is up off the mat -- now is the time to move

Posted Mar 22nd 2007 10:34AM by Gary Sattler (RSS feed)
Filed under: Good news, Products and Services, Competitive Strategy, Pfizer (PFE)

No doubt by now you have heard the good news regarding Pfizer Inc. (NYSE:PFE) and the shield it has in place for Celebrex. You can get some more insight on that by reading Douglas McIntyre's post.

Now the time is ripe for Pfizer to do something powerful. If it can accomplish one or two block buster product releases before mid-year, it'll be off to the races once again. In pursuit of that goal, Pfizer has a large stable of potential ground shakers in development. Here's an encapsulated view of what Pfizer has going right now in R&D:

I counted 49 formulations that Pfizer has in PHASE I of development. Of those compounds, ten are intended cancer treatments, eight are for inflammation and / or pain, including arthritis, 11 are directed towards cardiology, metabolic and endocrine conditions. Pfizer also has six compounds in PHASE I that are indicated for infectious diseases. Phase one drug testing focuses on compound safety rather than drug effectiveness.

Continue reading Pfizer is up off the mat -- now is the time to move